Press Release Details

Cerus Corporation Completes Stock Offering

March, 31 1999

CONCORD, Calif., March 31 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS) announced today its offering of 2,200,000 shares of common stock at $21.00 per share. Cerus has granted the underwriters an option to purchase an additional 330,000 shares solely to cover over-allotments, if any. The managing underwriters for the offering are Morgan Stanley & Co. Incorporated, BT Alex.Brown, Incorporated and SG Cowen Securities Corporation.

All of the shares sold were newly issued by Cerus. Cerus expects to use the net proceeds of the offering to fund research and development, including clinical trials, and for general and administrative expenses, capital expenditures and working capital.

Cerus Corporation is developing systems designed to enhance the safety of blood transfusions by inactivating pathogens in blood components (platelets, plasma and red blood cells used for transfusion) and by inactivating white blood cells, which are responsible for a variety of adverse transfusion reactions. The company's platform technologies, which prevent viral, bacterial and cellular replication, may have potential applications in the health care field beyond pathogen inactivation in blood components.

A prospectus relating to these securities may be obtained from Morgan Stanley & Co. Incorporated, 1585 Broadway, New York, NY 10036, Attention: Prospectus Department, BT Alex.Brown, Incorporated, One South Street, Baltimore, MD 21202, Attention: Prospectus Department and SG Cowen Securities Corporation, Four Embarcadero Center, Suite 1200, San Francisco, CA 94111, Attention: Prospectus Department.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any trials, regulations by the FDA, the uncertainty of replication of animal data in humans, the uncertainty of market acceptance of any products, competitive conditions, the uncertainty of future financing and other factors discussed in Cerus Corporation's 1998 Annual Report on Form 10-K.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600